GlobalData on MSN1mon
Zevra sells priority review voucher for $150m to support drug launchesZevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback